Sr. Director, Patient Marketing Dual Asset Strategy

argenx•Boston, MA

23h•$236,000 - $324,500

About The Position

argenx is transforming immunology and delivering medicines to help autoimmune patients. The company is undergoing multi-dimensional expansion, aiming to reach more patients through a rich pipeline of differentiated assets, including VYVGART, a first-in-class neonatal Fc receptor blocker approved for gMG, with potential for other severe autoimmune diseases. argenx is building a biotech company that maintains its science-based start-up roots while innovating across all business areas, striving to inspire and grow its company, partnerships, science, and people to deliver more for patients. The Senior Director, Patient Marketing & Commercial Strategy MMN-CIDP Franchise is a senior commercial leader responsible for maximizing the growth of Vyvgart Hytrulo in CIDP, while strategically preparing for and integrating the launch of Empa in MMN and subsequently CIDP, within a multi-indication therapeutic franchise. This role is part of the CIDP Indication Strategy Team and JIST, and oversees the patient commercial strategy across the portfolio, focusing on accelerating performance, expanding reach, and strengthening the positioning of Vyvgart Hytrulo in CIDP. Concurrently, this leader will collaborate with ICTs and cross-functional partners to define the dual-asset strategy and co-positioning framework to ensure the upcoming Empa launch enhances overall franchise value. Success requires balancing revenue growth for Vyvgart Hytrulo with long-term CIDP-MMN portfolio strategy, shaping the market to expand category demand, and building a cohesive enterprise narrative to maximize total franchise growth. argenx is a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, with a bold 2030 vision to reach 50,000 patients and transform autoimmune treatment.

Requirements

12-15+ years of biopharma commercial experience.
Demonstrated success driving performance of an in-market brand.
Launch experience.

Nice To Haves

Deep patient marketing expertise in specialty or rare disease markets.
Experience managing multi-asset or multi-indication portfolios.
MBA or advanced degree.

Responsibilities

Lead the development and evolution of patient commercial strategy to maximize growth across CIDP and MMN.
Identify and unlock growth levers across awareness, consideration, therapy initiation, persistence, and lifecycle management.
Strengthen competitive positioning and reinforce differentiated value within the treatment paradigm.
Drive omnichannel optimization using rigorous performance analytics and agile measurement.
Expand addressable market through targeted patient segment strategies and ecosystem partnerships.
Partner closely with HCP, Market Access, Medical, Patient Support Services and Patient Advocacy to remove friction points across the patient journey.
Co-Lead proactive competitive response planning and scenario modeling.
Define clear roles, positioning, and treatment sequencing for Vyvgart and Empa across CIDP and MMN.
Develop a franchise-level value narrative that clarifies differentiation while reinforcing complementary strengths.
Prevent internal cannibalization through disciplined segmentation and treatment pathway strategy.
Establish guardrails for patient engagement, messaging, targeting, and lifecycle investment decisions.
Lead trade-off discussions to optimize enterprise value versus individual brand preference.
Drive market shaping initiatives that grow category awareness and demand.
Lead disease awareness and unbranded education strategies to increase top-of-funnel volume.
Identify structural barriers (diagnostic delay, access constraints, patient inertia) and design strategic interventions.
Influence evidence generation priorities in partnership with Medical and Development to support long-term differentiation.
Anticipate competitive shifts and adapt ecosystem strategy accordingly.
Co-develop Patient Commercial Strategy for Empa MMN launch with disciplined alignment to franchise strategy.
Ensure Empa launch positioning complements and strengthens the in-market value of Vyvgart Hytrulo.
Define sequencing, patient targeting, and differentiation strategy.
Align US strategy with Global framework while advocating for market-specific needs.
Serve as a core strategic voice within the Indication Strategy Team.
Shape portfolio priorities and resource allocation decisions.
Provide executive-ready strategic recommendations supported by analytics and scenario modeling.
Mentor high-performing patient marketing talent.
Model enterprise mindset, cross-functional influence, and disciplined prioritization.